Link between inflammation and pancreatic cancer development uncovered
Study finds pancreatic cells are reprogrammed in response to inflammation, activating pathways that cooperate with mutant KRAS to promote tumor formation
MD Anderson News Release September 16, 2021
HOUSTON ― A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection between inflammation and pancreatic cancer development. According to the study published today in Science, pancreatic cells display an adaptive response to repeated inflammatory episodes that initially protects against tissue damage but can promote tumor formation in the presence of mutant KRAS.
The authors demonstrated that mutant KRAS — which is found in roughly 95% of all pancreatic cancers — supports this adaptive response, leading to selective pressure to maintain the cancer-causing mutation.
“We discovered that a single transient inflammatory event induced long-term transcriptomic and epigenetic reprogramming of epithelial cells that cooperated with oncogenic KRAS to promote pancreatic tumors long after the inflammation was resolved,” said corresponding author Andrea Viale, M.D., assistant professor of Genomic Medicine. “In the setting of repeated pancreatitis, KRAS mutations can be acquired early on to limit tissue damage, suggesting the existence of a strong evolutionary pressure to select mutated cells and providing a possible explanation for the nearly universal presence of mutant KRAS in pancreatic cancers.”
Clarifying the connection between inflammation and cancer
Inflammation has long been linked to tumor development in several cancer types, but the specific reasons behind this connection were previously unclear. The research team, led by co-first authors Edoardo Del Poggetto, Ph.D., postdoctoral fellow, and I-Lin Ho, graduate student in the Viale Laboratory, sought to study the effect of pancreatitis — a condition of inflammation in the pancreas linked with a higher risk of pancreatic cancer — on pancreatic epithelial cells.
The researchers stimulated transient inflammation in a model system of inducible KRAS-driven pancreatic cancer. Inflammation caused immediate pathological changes in pancreatic cells, but they resolved within one week. However, activation of KRAS even months following the resolution of inflammation resulted in accelerated tumor formation compared with controls, suggesting that inflammation drives long-term changes in epithelial cells that cooperate with mutant KRAS to promote cancer development.
Deep molecular analysis of epithelial cells following a single inflammatory event demonstrated substantial reprogramming of gene expression and epigenetic regulation that persisted long after recovery of the tissue damage, a process the researchers termed “epithelial memory.” This cellular reprogramming activated pathways related to cell survival, proliferation and embryonic development, which are similar to pathways active during cancer development.
Epithelial memory enables rapid response to limit tissue damage during recurrent pancreatitis
The cellular reprogramming caused by inflammation also facilitated the acquisition of acinar-to-ductal metaplasia (ADM), a reversible process in which pancreatic acinar cells acquire features of ductal cells. Acinar cells are responsible for producing and secreting digestive enzymes, while ductal cells are responsible for delivering those enzymes to the small intestine. ADM, a process that normally occurs in response to pancreatic damage, is thought to be a pancreatic cancer precursor.
In the context of epithelial memory, repeated inflammatory episodes resulted in the rapid and extensive appearance of ADM with minimal signs of cellular damage, suggesting that the cellular reprogramming protects the pancreas against an accumulation of tissue damage. These findings also clarify that ADM is not a cancer precursor state, but rather an adaptive response to inflammation.
Previous research has shown that KRAS mutations can induce and stabilize ADM. Here, the authors demonstrated that induction of mutant KRAS during repeated inflammations resulted in more pronounced ADM and virtually no tissue damage. Thus, the authors predict that cells undergoing inflammation would have a strong positive selection for KRAS mutations or other alterations that stimulate ADM and limit damage accumulations.
“We are working to better understand how cells maintain the epithelial memory we observed, but our data suggest that KRAS initially has a beneficial role during pancreatitis,” Ho said. “There may be similar phenomenon in other cancers with universal driver mutations, where there is a strong pressure to select those mutations based on some purpose unrelated to cancer development.”
The research team now is working to develop strategies to stimulate ADM in the pancreas while countering the selection pressure for mutated KRAS. If effective, the work may offer new treatments for pancreatitis that could also prevent pancreatic cancer development.
A full list of contributing authors and their disclosures can be found with the full paper here. This research was supported by the Cancer Prevention and Research Institute of Texas (CPRIT) (RP190599), the Andrew Sabin Family Fellowship, the V Foundation for Cancer Research (V2020-018), the National Institutes of Health/National Cancer Institute (P50CA221707, R01CA258917, P01 CA117969-12, 4R00CA218891-03, CA016672 and P30CA16672), MD Anderson’s Pancreatic Cancer Moon Shot®, the Pancreatic Cancer Action Network, the Associazione Italiana per la Ricerca sul Cancro, the Khalifa Bin Zayed Al Nahyan Foundation, the Marie Sklodowska-Curie Actions, the Pauline Altman-Goldstein Foundation Discovery Fellowship and institutional funding from MD Anderson.